ClinicalTrials.Veeva

Menu
O

ONCOVIDA | Santiago, Chile

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Belzutifan
Nivolumab
Lenvatinib
/Pembrolizumab
Platinum
MK-6482
Fianlimab
MK-2870
Bevacizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 23 total trials

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The prima...

Active, not recruiting
Melanoma
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic c...

Active, not recruiting
Colorectal Cancer
Drug: regorafenib
Biological: favezelimab/pembrolizumab

The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (...

Enrolling
Melanoma
Renal Cell Carcinoma
Biological: Pembrolizumab
Biological: Pembrolizumab co-formulated with hyaluronidase

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physici...

Enrolling
Breast Neoplasms
Drug: Liposomal doxorubicin
Drug: Sacituzumab tirumotecan

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in firs...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Nab-paclitaxel

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemipli...

Enrolling
Melanoma
Drug: Pembrolizumab
Drug: Fianlimab

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling
Melanoma
Drug: Cemiplimab
Drug: Placebo

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in pati...

Active, not recruiting
Prostatic Neoplasms
Other: Androgen deprivation therapy (ADT)
Drug: Placebo

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Carboplatin
Drug: Datopotamab Deruxtecan
Locations recently updated

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus ch...

Enrolling
Metastatic Esophageal Squamous Cell Carcinoma
Drug: Oxaliplatin
Drug: Levoleucovorin

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling
Solid Tumors
Hematologic Malignancies
Drug: Pembrolizumab
Drug: Lenvatinib

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A)...

Active, not recruiting
Ovarian Neoplasms
Uterine Cervical Neoplasms
Drug: Docetaxel
Drug: Gemcitabine
Locations recently updated

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tu...

Enrolling
Carcinoma, Hepatocellular
Biliary Tract Neoplasms
Drug: Pembrolizumab
Drug: Lenvatinib

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,...

Active, not recruiting
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Drug: Bevacizumab
Biological: Pembrolizumab

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to pr...

Enrolling
Carcinoma, Non-Small-Cell Lung
Biological: Pembrolizumab
Biological: Sacituzumab Govitecan

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting
Breast Neoplasms
Drug: dextrose
Drug: liposomal doxorubicin

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Daiichi Sankyo logo
Regeneron Pharmaceuticals logo
Amgen logo
Bayer logo
Nektar Therapeutics logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems